Katafan Achkar

Katafan Achkar

Auto-generated profile, based on publicly available information

Katafan Achkar

Department of Surgery, Houston Methodist J.C. Walter Jr. Transplant Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Advances in Kidney Disease and Health
Verified
Journal Article
Open access
KAKatafan A. Achkar
Katafan A. Achkar
LALama M. Abdelnour
Lama M. Abdelnour
BJBassam G. Abu Jawdeh
Bassam G. Abu Jawdeh
ETEkamol Tantisattamo
Ekamol Tantisattamo
FAFawaz Al Ammary
Fawaz Al Ammary
The evaluation of living kidney donor candidates is a complex and lengthy process. Donor candidates face geographic and socioeconomic barriers to completing donor evaluation. Inequities in access to living donations persist. With a growing demand for kidney transplants and a shortage of living donors, transplant centers are more permissive of accepting less-than-ideal donor candidates. Donors have an increased lifetime risk of kidney failure, but the absolute risk increase is small. Efforts are needed to support donor candidates to complete donor nephrectomy safely and efficiently and receive optimal follow-up care to prevent risk factors for kidney disease and detect complications early. In this article, the authors address key elements of donor kidney evaluation, including current living donation policy requirements and transplant center practices. The authors present a simplified comprehensive practical approach to help guide providers in completing donor evaluation and follow-up care with best outcomes possible.

26 February 2026 in American Journal of Transplantation
Verified
Journal Article
Open access
KAKatafan Achkar
Katafan Achkar
FAFawaz Al Ammary
Fawaz Al Ammary
MAMuhammad Abdul-Ghani
Muhammad Abdul-Ghani
THTim Heise
Tim Heise
ASArchana R. Sadhu
Archana R. Sadhu
AGAhmed Osama Gaber
Ahmed Osama Gaber
The consideration of individuals with prediabetes for living kidney donation remains challenging, largely due to the lack of consensus on how best to evaluate the degree of impaired glucose homeostasis and the long-term risk of developing diabetes mellitus, a significant risk factor for kidney disease. Traditional biomarkers such as hemoglobin A1c lack sensitivity for early detection of impaired glucose homeostasis, while the oral glucose tolerance test, although more informative, has only moderate reproducibility for identifying impaired fasting glucose and impaired glucose tolerance. Notably, many individuals with normal hemoglobin A1c and fasting plasma glucose levels may still be at elevated risk for progression to diabetes. In this personal viewpoint, we highlight the utility of published prognostic markers/indices derived from oral glucose tolerance test data to improve risk stratification for living kidney donor candidates with impaired glucose homeostasis. We also propose a list of high-risk markers that can help identify living kidney donors who are at increased risk for diabetes mellitus.

2 June 2026 in Kidney Medicine
Verified
Journal Article
Open access
KAKatafan Achkar
Katafan Achkar
SYStephanie Yi
Stephanie Yi
GNGeorge M. Nassar
George M. Nassar
AKAbdul-Jabbar Khan
Abdul-Jabbar Khan
PSPaul M. Schroder
Paul M. Schroder
AGAhmed Osama Gaber
Ahmed Osama Gaber
Antiphospholipid syndrome (APS) is associated with an increased risk of thrombotic complications after kidney transplantation, particularly in patients with persistently elevated and triple-positive antiphospholipid antibodies (aPLs). Management of APS in kidney transplantation relies primarily on perioperative anticoagulation; however, thrombotic events may still occur despite appropriate therapy in patients with high-risk aPLs. We report the case of a 49-year-old woman with systemic lupus erythematosus-associated APS and persistently triple-positive aPLs who underwent living donor kidney transplantation. Because of her high thrombotic risk, perioperative immunoglobulin G--lowering therapy with the neonatal Fc receptor antagonist efgartigimod alfa was administered in addition to therapeutic anticoagulation. Treatment with efgartigimod alfa was associated with marked reductions in anticardiolipin and anti-β2-glycoprotein I antibody levels before transplantation, conversion of lupus anticoagulant to negative after transplantation, and sustained suppression of aPLs during the early posttransplant period. Kidney transplantation was successful with stable graft function during follow-up. To our knowledge, this represents the first reported use of efgartigimod alfa to reduce aPLs in the perioperative management of APS in kidney transplantation.